Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate

Oncotarget

Volumn 7, Issue 50, 2016, Pages 82504-82510

  Schweizer, Michael T ^a,b   Cheng, Heather H ^a,b   Tretiakova, Maria S ^c   Vakar Lopez, Funda ^c   Klemfuss, Nola ^b   Konnick, Eric Q ^c   Mostaghel, Elahe A ^a,b   Nelson, Peter S ^a,b   Yu, Evan Y ^a,b   Montgomery, Bruce ^a,b   True, Lawrence D ^c   Pritchard, Colin C ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Ductal adenocarcinoma; Hypermutation; Microsatellite instability; Mismatch repair; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA SEQUENCE; GENE; GENE MUTATION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERMUTATION; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MISMATCH REPAIR DEFICIENCY; MMR GENE; NEXT GENERATION SEQUENCING; PROSTATE ADENOCARCINOMA; PROSTATE DUCTAL ADENOCARCINOMA; TUMOR BIOPSY; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; MISMATCH REPAIR; MORTALITY; MUTATION; PAGET NIPPLE DISEASE; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; PROSTATECTOMY; SECONDARY; TREATMENT OUTCOME;

DNA BINDING PROTEIN; DNA MISMATCH REPAIR PROTEIN MSH2; G-T MISMATCH-BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; MUTL PROTEIN HOMOLOG 1; TUMOR MARKER;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, DUCTAL; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTL PROTEIN HOMOLOG 1; MUTS HOMOLOG 2 PROTEIN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 85003819933     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12697     Document Type: Article

References (24)

1. Bessa X, Alenda C, Paya A, Alvarez C, Iglesias M, Seoane A, Dedeu JM, Abuli A, Ilzarbe L, Navarro G, Pellise M, Balaguer F, Castellvi-Bel S, et al. Validation microsatellite path score in a population-based cohort of patients with colorectal cancer. J Clin Oncol. 2011; 29:3374-80. doi: 10.1200/jco.2010.34.3947.
2. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008; 111:2505-15. doi: 10.1182/blood-2007-07-102798.
3. Shia J, Ellis NA, Paty PB, Nash GM, Qin J, Offit K, Zhang XM, Markowitz AJ, Nafa K, Guillem JG, Wong WD, Gerald WL, Klimstra DS. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol. 2003; 27:1407-17.
4. Fenton PA, Clarke SE, Owen W, Hibbert J, Hodgson SV. Cribriform variant papillary thyroid cancer: a characteristic of familial adenomatous polyposis. Thyroid. 2001; 11:193-7. doi: 10.1089/105072501300042965.
5. Sainty D, Liso V, Cantu-Rajnoldi A, Head D, Mozziconacci MJ, Arnoulet C, Benattar L, Fenu S, Mancini M, Duchayne E, Mahon FX, Gutierrez N, Birg F, et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood. 2000; 96:1287-96.
6. (2016). WHO Classification of Tumoours of the Urinary System and Male Genital Organs: World Health Organization.
7. Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology. 2012; 60:59-74. doi: 10.1111/j.1365-2559.2011.04039.x.
8. Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol. 1999; 23:1471-9.
9. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol. 2009; 22:1176-85. doi: 10.1038/modpathol.2009.79.
10. Morais CL, Herawi M, Toubaji A, Albadine R, Hicks J, Netto GJ, De Marzo AM, Epstein JI, Lotan TL. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. Prostate. 2015; 75:1610-9. doi: 10.1002/pros.23042.
11. Sanati S, Watson MA, Salavaggione AL, Humphrey PA. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol. 2009; 22:1273-9. doi: 10.1038/modpathol.2009.103.
12. Pritchard CC, Salipante SJ, Koehler K, Smith C, Scroggins S, Wood B, Wu D, Lee MK, Dintzis S, Adey A, Liu Y, Eaton KD, Martins R, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn. 2014; 16:56-67. doi: 10.1016/j.jmoldx.2013.08.004.
13. Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, Salipante SJ, Milbank J, Yu M, Grady WM, Tait JF, Corey E, Vessella RL, et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun. 2014; 5:4988. doi: 10.1038/ncomms5988.
14. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161:1215-28. doi: 10.1016/j.cell.2015.05.001.
15. Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol. 2010; 184:2303-7. doi: 10.1016/j.juro.2010.08.017.
16. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371:2189-99. doi: 10.1056/NEJMoa1406498.
17. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372:2509-20. doi: 10.1056/NEJMoa1500596.
18. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387:1909-20. doi: 10.1016/s0140-6736(16)00561-4.
19. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366:2443-54. doi: 10.1056/NEJMoa1200690.
20. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science. 2013; 339:1546-58. doi: 10.1126/science.1235122.
21. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-7. doi: 10.1038/nature11252.
22. Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM. Early evidence of anti-PD-1 activity in enzalutamideresistant prostate cancer. Oncotarget. 2016; doi: 10.18632/oncotarget.10547.
23. Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem. 2014; 60:1192-9. doi: 10.1373/clinchem.2014.223677.
24. Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de la Chapelle A, Pritchard CC. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014; 147:1308-16.e1. doi: 10.1053/j. gastro.2014.08.041.